Inhibrx Biosciences (INBX) investor relations material

Executive summary

• Clinical-stage biopharma focused on oncology, advancing ozekibart (INBRX-109) and INBRX-106 in multiple solid tumor indications, with recent positive clinical data and regulatory submissions.

• Announced interim and pivotal results for ozekibart in colorectal cancer, Ewing sarcoma, and chondrosarcoma, including a BLA submission for chondrosarcoma in April 2026.

• INBRX-106 showed promising Phase 2 results in HNSCC, with plans to initiate Phase 3 and expand into additional indications.

Financial highlights

• Cash and cash equivalents were $161.7 million as of March 31, 2026, up from $124.2 million at December 31, 2025.

• Net loss for Q1 2026 was $33.4 million, a 23% improvement from $43.3 million in Q1 2025.

• Research and development expenses decreased 32% year-over-year to $25.2 million, mainly due to lower clinical and manufacturing costs as trials neared completion.

• General and administrative expenses were $5.7 million, down slightly from $6.0 million year-over-year.

• Interest expense increased to $3.5 million due to additional debt financing.

Outlook and guidance

• Existing cash is expected to fund operations for at least the next 12 months.

• Plans to meet with the FDA in the second half of 2026 for potential accelerated pathways for ozekibart in colorectal cancer and Ewing sarcoma.

• Phase 3 trial for INBRX-106 in HNSCC to begin in Q3 2026, with further expansion into NSCLC and other indications.

• Anticipates increased R&D and pre-commercialization expenses as programs advance.